Trevi Therapeutics Inc (TRVI) Q3 2024 Earnings Call Highlights: Navigating Increased Losses and ... [Yahoo! Finance]
Trevi Therapeutics, Inc. (TRVI)
Company Research
Source: Yahoo! Finance
G&A Expenses: $2.9 million in Q3 2024, compared to $2.7 million in Q3 2023. Cash Equivalents and Marketable Securities: $65.5 million as of September 30, 2024, down from $83 million as of December 31, 2023. Cash Burn Guidance: Expected to be between $41 million and $43 million for 2024. Cash Runway: Projected into the second half of 2026. Warning! GuruFocus has detected 3 Warning Signs with TRVI. Release Date: November 06, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript Trevi Therapeutics Inc ( NASDAQ:TRVI ) has made significant progress in its clinical development plans, particularly in chronic cough and idiopathic pulmonary fibrosis (IPF) trials. The company has a strong cash position with $65.5 million in cash equivalents and marketable securities, providing a cash runway into the second half of 2026. Trevi Therapeutics Inc ( NASDAQ:TRVI ) has successfully completed enrollment in its RCC trial and is on tra
Show less
Read more
Impact Snapshot
Event Time:
TRVI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRVI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRVI alerts
High impacting Trevi Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TRVI
News
- Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.MarketBeat
- Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdatesPR Newswire
- Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024PR Newswire
- Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.MarketBeat
- Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic CoughPR Newswire
TRVI
Earnings
- 11/6/24 - Miss
TRVI
Sec Filings
- 11/14/24 - Form SC
- 11/13/24 - Form SC
- 11/8/24 - Form SC
- TRVI's page on the SEC website